Eli Lilly and Company Depositary Receipt logo

Eli Lilly and Company Depositary Receipt (LLY80)

Market Closed
11 Aug, 23:30
SET SET
฿
2. 02
+0.08
+4.1237%
฿
- Market Cap
104.2 P/E Ratio
- Div Yield
704,232 Volume
6.64 Eps
฿ 1.94
Previous Close
Add Transaction
Day Range
2.02 2.04
Year Range
1.01 2.1
Want to track LLY80 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

LLY80 closed today higher at ฿2.02, an increase of 4.1237% from yesterday's close, completing a monthly decrease of -0.9804% or -฿0.02. Over the past 12 months, LLY80 stock gained 18.1287%.
LLY80 is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.

LLY80 Chart

Eli Lilly and Company Depositary Receipt (LLY80) FAQ

What is the stock price today?

The current price is ฿2.02.

On which exchange is it traded?

Eli Lilly and Company Depositary Receipt is listed on SET.

What is its stock symbol?

The ticker symbol is LLY80.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Eli Lilly and Company Depositary Receipt ever had a stock split?

No, there has never been a stock split.

Eli Lilly and Company Depositary Receipt Profile

Pharmaceuticals Industry
Healthcare Sector
David A. Ricks CEO
SET Exchange
- ISIN
US Country
50,000 Employees
- Last Dividend
- Last Split
13 Jan 1978 IPO Date

Overview

Eli Lilly and Company is a global leader in the discovery, development, and marketing of human pharmaceuticals. With a history dating back to 1876, the company has established itself as a key player in the pharmaceutical industry, offering a wide range of products aimed at treating a variety of conditions. Headquartered in Indianapolis, Indiana, Eli Lilly and Company has forged multiple collaborations with other pharmaceutical giants such as Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd., enhancing its product offerings and research capabilities across different therapeutic areas.

Products and Services

  • Diabetes Care

    Includes a comprehensive portfolio of insulin and other diabetes treatments: Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. Additionally, the company offers Jardiance, Mounjaro, and Trulicity for managing type 2 diabetes.

  • Oncology

    Provides a range of products for cancer treatment, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio, focusing on different types of cancer and treatment approaches.

  • Immunology

    Olumiant is offered for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19. Taltz is available for treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.

  • Digestive Diseases

    Omvoh is targeted at ulcerative colitis, reflecting the company's commitment to addressing gastrointestinal disorders.

  • Neurological Disorders

    Includes Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is provided for migraine prevention and treatment of episodic cluster headache.

  • Other Therapeutic Areas

    The company also offers Cialis for erectile dysfunction and benign prostatic hyperplasia; Forteo for osteoporosis treatment; Zepbound for obesity management; and Ebglyss for severe atopic dermatitis, showcasing Eli Lilly's diverse portfolio catering to various health conditions.

Contact Information

Address: Lilly Corporate Center
Phone: 317 276 2000